Skip to main content

Table 6 Comparison of CHEK2 mutation frequency in patients with selected tumours and in the control group

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Location or type of tumour Number of tested Number of mutation carriers (frequency), results of statistical analysis*
   IVS2+1G>A 1100delC 1100delC or IVS2+1G>A I157T
Bladder 172 1 (0.6%)   1 (0.6%) 12 (7.0%)
   OR = 1.2 0 OR = 0.8 OR = 1.5
   p = 0.7   p = 0.8 p = 0.3
Kidney 264 0 2 (0.8%) 2 (0.8%) 26 (9.8%)
    OR = 2.7 OR = 1.0 OR = 2.1
    p = 0.5 p = 0.8 p = 0.0006
Larynx 245 0 0 0 10 (4.1%)
OR = 0.8
p = 0.7
Lung 272 0 0 0 7 (2.6%)
OR = 0.5
p = 0.1
Melanoma 129 2 (1.5%)
OR = 3.3
p = 0.3
1 (0.8%)
OR = 3.1
p = 0.8
3 (2.3%)
OR = 3.2
p = 0.1
6 (4.6%)
OR = 1.0
p = 0.9
Ovary 292 0 0 0 14 (4.8%)
OR = 1.0
p = 0.9
Stomach 241 4 (1.7%)
OR = 3.5
p = 0.05
0 4 (2.1%)
OR = 2.3
p = 0.2
13 (5.4%)
OR = 1.1
p = 0.8
NHL 120 1 (0.8%)
OR = 1.8
p = 0.9
0 1 (0.8%)
OR = 1.1
p = 0.7
11 (9.2%)
OR = 2.0
p = 0.05
Pancreas 93 0 0 0 6 (6.4%)
OR = 1.4
p = 0.6
Thyroid 173 5 (2.9%)
OR = 6.2
p = 0.0003
1 (0.6%)
OR = 2.3
p = 0.9
6 (3.5%)
OR = 4.9
p = 0.0006
15 (8.7%)
OR = 1.9
p = 0.04
Controls 4000 19 (0.475%) 10 (0.25%) 29 (0.725%) 193 (4.825%)
  1. *comparison of CHEK2 mutation frequency in patients with specific tumour type to that of control group
  2. NHL – non-Hodgkin lymphoma; OR – odds ratio; p – p-value